trending Market Intelligence /marketintelligence/en/news-insights/trending/dcfmpuq9uttpvhyryeshnw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Oncobiologics names board member

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Oncobiologics names board member

Cranbury, N.J.-based Oncobiologics Inc. appointed Joerg Windisch to its board, replacing Yezan Haddadin who resigned.

Windisch, a nominee of Oncobiologics shareholder GMS Tenshi Holdings Pte. Ltd., is COO of Polish biotechnology company Polpharma Biologics. He has worked at Sandoz Biopharmaceuticals for two decades, most recently as chief science officer.

"Joerg is an experienced industry executive and scientist with over 20 years in the development of biological therapeutics. His broad expertise in biosimilar development, manufacturing and regulatory affairs will support our work in further developing our biosimilar product candidate pipeline in the years ahead," Oncobiologics Chairman and CEO Pankaj Mohan said in a statement.

Sandoz Inc. is a Novartis AG unit.